Monthly Archives: May 2013

NanoPass Technologies is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. The study is a phase 3, open-label, randomized clinical trial comparing immune response after receiving one of five different combinations...

Sony Corporation has invested $10 million in Rainbow Medical, an Israeli investment group and developer of medical device companies. Previous investors in Rainbow Medical include Medtronic Inc. (NYSE: MDT), Abbott Laboratories Inc. (NYSE: ABT), and Italy’s Sorin. Rainbow Medical, which invests in the inventions of serial entrepreneur Yossi Gross, is...

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced that the first patient has been treated in the Company’s phase I clinical trial of PRX-112, or Oral GCD, the Company’s orally-administered enzyme product candidate for the treatment of Gaucher disease. Oral GCD is a plant cell expressed form of the glucocerebrosidase enzyme...

Gamida Cell announced additional analyses for the Phase II/III, multi-center, multi-national, historical cohort-controlled study to evaluate efficacy and safety of StemEx® as an alternative transplantation treatment for patients with high risk leukemia and lymphoma. Twenty-five bone marrow transplant centers worldwide treating 101 patients with hematologic malignancies following myeloablative therapy who...

BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) announced positive results for the Phase IIa clinical trial of BL-7040, an oral treatment for inflammatory bowel disease (IBD). The study found that BL-7040 is safe and effective in treating ulcerative colitis, a form of IBD. The drug was also well tolerated by the study...

Brainsway Ltd. (TASE:BRIN) has started sales of its Deep TMS (transcranial magnetic stimulation) device in the US for non-invasive treatment of major depression, after completing production of the first 100 devices at a standard suitable for marketing. Brainsway will unveil the Deep TMS for the US market at the American...

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that United Therapeutics Corporation has received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). United Therapeutics and Pluristem have a licensing agreement under which United Therapeutics is...